Oral Decitabine/Cedazuridine with Venetoclax versus oral Decitabine/Cedazuridine in high-risk Myelodysplastic Syndrome: A propensity score matched analysis

Assessment of clinical outcomes of patients with Myelodysplastic Syndromes (MDS) who were treated with oral Decitabine/Cedazuridine (DEC-C) using the International Working Group (IWG) 2023 criteria